Anschutz | Cancer Center

Open Clinical Trials

March 2026

To refer a patient, please contact the disease specific nurse navigator directly to schedule a visit with one of our providers.

Please note that slot status may vary over time.

For more information regarding trials at the University of Colorado, please visit:
https://researchstudies.cuanschutz.edu/

Jump to Cancer Types

Common Eligibility Criteria for Clinical Trials

Location Key	
AMC	Anschutz Medical Campus, Anschutz Cancer Pavilion, 1665 Aurora Ct, Aurora, CO 80045
CCMC	Cherry Creek Medical Center, 100 Cook St, Denver, CO 80206
HRH	Highlands Ranch Hospital, 1500 Park Central Dr, Highlands Ranch, CO 80129
LT	Lone Tree Medical Center, 9548 Park Meadows Dr, Lone Tree, CO 80124

Satellite Site Contacts

Breast Cancer Medical Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Jane Jachowicz, BSN, RN	Jane.jachowicz@uchealth.org	Phone: 720-848-3537 Fax: 720-848-1774
Sara Johnson, BSN, RN	Sara.johnson@uchealth.org	Phone: 720-848-9237 Fax: 720-848-1774
Physician Leads	**Email**	**Phone**
Virginia Borges, MD	Virginia.borges@cuanschutz.edu	
Peter Kabos, MD	Peter.kabos@cuanschutz.edu	
Jennifer Diamond, MD	Jennifer.diamond@cuanschutz.edu	

Metastatic Breast Cancer			
Study Name	**Patients**	**NCT#**	**Sites**
Phase I study of OP-1250 (Palazestrant) with ribociclib, alpelisib, everolimus, or atirmociclib (22-1277)	Advanced/Metastatic ER+, HER2- breast cancer	NCT05508906	AMC
PRE-I-SPY Phase 1/1b Platform, PRE-Investigation of Serial Studies (24-1242)	Previously treated metastatic breast cancer	NCT05868226	AMC
Phase 3 trial of saruparib (PARP1i) plus camizestrant (SERD) vs MD choice of CDK4/6 plus endocrine therapy (24-1711)	ER+, HER2-, BRCA1, BRCA2 or PALB2 mutations	NCT06380751	AMC
Phase 3 Study of MK-2870 (Sac-TMT, ADC) +/- pembromizumab vs physician's choice therapy (24-1416)	HR+/HER2-negative metastatic breast cancer	NCT06312176	AMC CCMC HRH
Phase 2 trial of nab-paclitaxel, durvalumab, tremelimumab +/- vaccine (19-0013)	1L metastatic TNBC	NCT03606967	AMC
Phase 2 study of tucatinib, eribulin, trastuzumab (22-1407)	Previously treated metastatic HER2+ breast cancer	NCT05458674	AMC
PIKture-01 Phase 1 OKI-219 (mutant selective PI3K H1047R inhibitor) (24-0016)	Previously treated metastatic solid tumors with PI3K H1047R mutation	NCT06239467	AMC
Phase 3 CDK4/6i + fulvestrant +/- capivasertib (AKTi) (21-3077)	1L metastatic HR+HER2- breast cancer	NCT04862663	AMC, CCMC
Phase 1 study of STX-478 (mutant selective PI3K inhibitor) (23-0200)	Metastatic HR+HER2- breast cancer with PIK3CA mutation	NCT05768139	AMC (POEMs)
Phase 3 study OP-1250 (SERD) (23-2036)	Metastatic HR+HER2-	NCT06016738	AMC, HRH, CCMC, LT
Phase 3 study of zanidatamab (HER2 bispecific ab) + standard therapy v. trastuzumab + standard therapy (24-1635)	Previously treated metastatic HER2+ breast cancer	NCT06435429	AMC, HRH, CCMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab (24-1128)	Previously treated metastatic HR+HER2- or TNBC, ovarian cancer	NCT06233942	AMC (POEMs)
Phase 1/2 study of MBRC-101 in select advanced solid tumors (23-2430)	Metastatic breast cancer	NCT06014658	AMC (POEMs)

CDK4/6 Inhibitor dosing knowledge (CDK) study (24-1798)	Metastatic breast cancer in older adults	NCT06377852	AMC
Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced Cancers Harboring HER2 tyrosine kinase domain mutations or HER2+	NCT06253871	AMC (POEMs)
Phase 2 study of zelenectide (ADC) (25-0193)	NECTIN4 Amplified Advanced HR+ HER2- or TNBC	NCT06840483	AMC
Phase II study of utidelone (UTD1) + capecitabine (25-0715)	HER2-negative Metastatic Breast Cancer Patients with Brain Metastases	NCT06764940	AMC
An Open-Label, Multicenter, Phase Ib Dose Randomization Study of Bulumtatug Fuvedotin (BF; 9MW2821) in Subjects with Recurrent or Metastatic Triple-Negative Breast Cancer Previously Treated with Antibody-drug Conjugates (25-1309)	Recurrent or metastatic TNBC that has received prior treatment with a taxane and an antibody-drug conjugate with a topoisomerase inhibitor payload	NCT06908928	AMC
An Open-label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects with Known Wnt-Pathway Activated Solid Tumors Where No Other Treatments Exist (25-2381)	Solid Tumors known to be Wnt-Pathway activated (TNBC) with no other approved treatment options available	NCT07312903	AMC (POEMs)
Early-Stage Breast Cancer			
ISPY2.2 neoadjuvant study (10-0374)	Stage II-III Breast cancer	NCT01042379	AMC, LT, HRH, CCMC
DARE: Phase 2 trial of ctDNA-guided treatment (20-2773)	High risk HR+HER2-	NCT04567420	AMC, LT, HRH, CCMC
OFSET: Phase 3 study of chemotherapy v. ovarian suppression (23-2461)	Premenopausal HR+HER2- breast cancer	NCT05879926	AMC, LT, HRH, CCMC
OptimICE-PCR: De-escalation after pCR (23-1255)	TNBC with pCR to neoadjuvant therapy	NCT05812807	AMC, LT, HRH
Tailor RT: Randomized study regional RT in low-risk node+ or T3N0 breast cancer (19-0476)	Low-risk node+ or T3N0M0 breast cancer following surgery	NCT03488693	AMC, CCMC, HRH, LT (RT Group)
NRG-BR007: DEBRA: Phase 3 trial of de-escalation of RT in Stage I HR+HER2- breast cancer (21-4582)	Stage I, HR+, HER2- breast cancer with Oncotype RS $\leq$ 18	NCT04852887	AMC, CCMC, HRH (RT Group)
S2206: Phase 3 trial of neoadjuvant durvalumab (PD-L1i) plus chemo vs chemo alone (24-0401)	MammaPrint ultrahigh ER/PR+, HER2-	NCT06058377	AMC, LT, HRH, CCMC
CAMBRIA-2: Phase 3 trial of adjuvant camizestrant (SERD) vs standard endocrine therapy (24-1414)	ER+/HER2-; intermediate-high or high risk for recurrence following definitive treatment, currently NED	NCT05952557	AMC, HRC, CCMC
S2212 SCARLET: Shorter Anthracycline-Free Chemo Immunotherapy in Early TNBC (23-2438)	Early Stage TNBC	NCT05929768	AMC, CCMC LT HRH

Cutaneous Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Nurse navigator	melanoma@uchealth.org	Phone: 720-848-0505 Fax: 720-848-0614
Physician	**Email**	**Phone**
Sapna Patel, MD	Sapna.p.patel@cuanschutz.edu	

High-Risk Resected Melanoma			
No current trials available			
Advanced Melanoma			
Phase 2/3 study of LNS8801 (GPER agonist) +/- without pembrolizumab (25-0336)	Treatment refractory, unresectable melanoma	NCT06624644	AMC
TILVANCE-301: Phase 3 trial of Lifileucel (LN-144 tumor infiltrating lymphocyte) + pembro vs pembro alone (24-0982)	Untreated, unresectable or metastatic melanoma	NCT05727904	AMC
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors (22-1490)	1L NSCLC PD-L1 TPS $\geq$ 50% 1L PD-L1+ melanoma 2L PD-L1+ melanoma	NCT05533697	AMC (POEMs)
IGNYTE-3: Phase 3 trial of vusolimogene oderparepvec (oncolytic virus) + nivolumab v. treatment of physician's choice (24-1672)	Advanced melanoma progressed on Anti-PD-1 and Anti-CTLA-4	NCT06264180	AMC
Phase 3 trial of fianlimab + cemiplimab vs relatlimab (LAG-3i) and nivolumab (24-1713)	Unresectable or metastatic melanoma	NCT06246916	AMC
SUPRAME: Open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma(25-0844)	HLA-A*02:01 positive, Disease progression (resistance or toxicity) on at least 1 PD-1 inhibitor	NCT06743126	AMC
Phase 1 study of PF-07799933 (RAFi) in advanced tumors with BRAF alterations (22-1125)	Metastatic melanoma with BRAF V600E mutation post BRAF/MEKi and IO	NCT05355701	AMC (POEMs)
Neoadjuvant or Resectable Melanoma			
Uveal Melanoma			
REVEAL: Phase 2/3 Study of RP2 (oncolytic virus) + nivolumab v. ipilimumab + nivolumab (25-0004)	Immune checkpoint inhibitor-naïve metastatic uveal melanoma; no more than 2 lines of systemic therapy	NCT06581406	AMC
TARGET-Tebe: A Phase II Study of KIMMTRAK in HLA-A*0201 Positive Untreated Metastatic Uveal Melanoma with Integrated Circulating Tumor DNA (25-2068)	Untreated Metastatic Uveal Melanoma positive for HLA-A*0201	NCT06070012	AMC
Phase 1/2 study evaluating genetically modified autologous T	Recurrent and/or refractory uveal melanoma	NCT03686124	AMC

cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine® IMA203-101) (25-2206)			
Merkel Cell Carcinoma, Squamous Cell Carcinoma			
	Advanced or metastatic merkel cell carcinoma	NCT06947928	AMC
Advanced Cutaneous Malignancies in Transplant Recipients			
Phase 1b/2 study of RP1 (oncolytic virus) (19-2987)	Solid organ or hematopoietic cell transplant recipient	NCT04349436	AMC
Phase 1 / 2 Study of REGN7075 (EGFRxCD28 bispecific ab) + cemiplimab (24-2232)	Select advanced solid tumors, including cutaneous squamous cell carcinoma, CRC, HNSCC	NCT04626635	AMC (POEMs)

Gastrointestinal Oncology Anschutz Medical Campus (AMC)		
Nurse Navigators	**Email**	**Phone**
Kristen Miller	Kristen.Miller3@uchealth.org	Phone: 720-848-2639
Natalya Veneychuk	Natalya.Veneychuk@uchealth.org	Phone: 720-848-5456
Marcela Mora (Spanish speaking)	Marcela.Mora@uchealth.org	Phone: 720-848-5474
Physicians	**Email**	**Phone**
Lindsey Davis, MD	Sarah.Davis@cuanschutz.edu	
Chris Lieu, MD	Christopher.Lieu@cuanschutz.edu	
Wells Messersmith, MD	Wells.Messersmith@cuanschutz.edu	

Gastric, Gastroesophageal, and Gastroesophageal Junction (GEJ) Cancers			
Phase 3 study of rilvegostomig (bispecific ab) + fluoropyrimidine + trastuzumab deruxtecan v. trastuzumab, chemotherapy + pembrolizumab (ARTEMIDE-Gastric01/25-0646) (25-0646)	1L HER2 gastric cancer	NCT06764875	AMC
Phase 1 study of SGN-CEACAM5C advanced solid tumors including CRC, GC/GEJ, pancreatic cancer (23-2329)	2L+ advanced CRC, GC/GEJ or pancreatic cancer	NCT06131840	AMC
Phase 1 study of TJ033721 in metastatic gastric, GE and esophageal adenocarcinoma (21-3254)	1L metastatic gastric, GE, and esophageal adeno ca positive for CLDN18.2	NCT04900818	AMC
CHS-114-102: Phase 1b study of CHS-114 (anti-CCR8ab) + toripalimab +/- other treatments (25-1556)	2L Gastric, GEJ and Esophageal Adenocarcinoma and 2L esophageal squamous cell carcinoma	NCT06657144	AMC
Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced Cancers Harboring HER2 tyrosine kinase domain mutations or HER2+	NCT06253871	AMC (POEMs)
An Open-label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects with Known Wnt-Pathway Activated Solid Tumors Where No Other Treatments Exist (25-2381)	Solid Tumors known to be Wnt-Pathway activated (Gastric) with no other approved treatment options available	NCT07312903	AMC (POEMs)
Early-Stage Colorectal Cancer (CRC)			
CIRCULATE-US: Colon adjuvant chemotherapy based on evaluation of residual disease (22-0916)	Stage IIIA/B MSS colon adenocarcinoma following curative resection	NCT05174169	AMC, LT, HRH, CCMC
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients with Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates (25-1202)	MMR-Proficient low-mid rectal adenocarcinoma cT1-4, N0-2, M0	NCT07292298	AMC (RT Group)
Metastatic Colorectal Cancer (CRC)			
Phase I trial of AWN003694 + cetuximab + encorafenib (25-0300)	Refractory BRAF V600E metastatic CRC	NCT06102902	AMC
Study of RAS (ON) inhibitors in GI tumors in combination with standard therapies (24-1326)	1-3L metastatic RAS-mutated CRC, 1-2L	NCT06445062	AMC, LT

	metastatic RAS-mutated pancreatic cancer		
OrigAMI-3: Phase 3 study of FOLFIRI + amavantamab v cetuximab/bevacizumab in metastatic CRC (24-2380)	2L metastatic CRC KRAS/NRAS and BRAF WT	NCT06750094	AMC
INTRINSIC: Phase 1/1b umbrella study of targeted therapies in metastatic CRC (21-3774)	Previously treated advanced or metastatic CRC with PIK3CA mutation +/- RAS mutation	NCT04929223	AMC
CARAPIA-1: Phase 1 study of GCC19CART in metastatic CRC. *This trial requires hospitalization and inpatient delivery of study drug for some cycles* (22-0697)	Previously treated metastatic CRC, GCC+, MSS	NCT05319314	AMC
Phase 1 study of PF-07799933 (RAFi) in advanced tumors with BRAF alterations (22-1125)	Metastatic CRC with BRAF V600E mutation	NCT05355701	AMC (POEMs)
Phase 1 study of SGN-CEACAM5C advanced solid tumors including CRC, GC/GEJ, pancreatic cancer (23-2329)	2L+ advanced CRC, GC/GEJ or pancreatic cancer	NCT06131840	AMC
AE2222: PUMP: Phase 3 study of systemic therapy +/- hepatic arterial infusion for unresectable CRC liver mets (24-0029)	Unresectable liver metastatic CRC	NCT05863195	AMC
Phase 1 study of JNJ-89402638 (bispecific ab) for metastatic CRC (24-1600)	3L+ unresectable metastatic CRC	NCT06663319	AMC
Phase 1 study of BI1831169 (oncolytic virus) +/- ezabenlimab (anti-PD-1) in advanced solid GI tumors (23-2048)	Advanced or metastatic GI tumors with no standard therapies	NCT05155332	AMC
Phase 1 study of PF-07934040 (KRASi) in patients (24-1423)	Select advanced solid tumors with KRAS mutations	NCT06447662	AMC (POEMs)
CHS-114-102: Phase 1b study of CHS-114 (anti-CCR8) + toripalimab with or without other treatments in participants with advanced or metastatic solid tumors (25-1556)	4L + CRC	NCT06657144	AMC
An Open-label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects with Known Wnt-Pathway Activated Solid Tumors Where No Other Treatments Exist (25-2381)	Solid Tumors known to be Wnt-Pathway activated(CRC) with no other approved treatment options available	NCT07312903	AMC (POEMs)
Liver Cancer			
Phase Ib/2 study of multiple immunotherapy based treatment combinations (24-1787)	Locally advanced/metastatic /unresectable HCC; no priory treatment	NCT04524871	AMC, HRH, CCMC
Phase 1b/2 study of TTI-101 in advanced or metastatic HCC (22-1621)	1-3L Unresectable, locally advanced or metastatic HCC	NCT05440708	AMC
Biliary Tract Cancer			
Protocol 10608, A phase II trial of durvalumab with gemcitabine and cisplatin as neoadjuvant therapy for high-risk resectable intrahepatic cholangiocarcinoma (24-0573)	Resectable intrahepatic cholangiocarcinoma	NCT06050252	AMC

Phase 1/2 study of patritumab deruxtecan (ADC) (24-1883)	2L + Biliary Tract Cancer	NCT06596694	AMC
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (24-1250)	Cohort 3 – 2L Biliary Tract Cancer Cohort 4 – 1L Biliary Tract Cancer	NCT06428409	AMC, HRH, CCMC
Pancreatic Cancer			
Intraperitoneal paclitaxel for pancreatic ductal adenocarcinoma (24-2111)	Pancreatic Ductal Adenocarcinoma with Peritoneal Carcinamatosis	NCT07030283	AMC
Study of RAS (ON) inhibitors in GI tumors in combination with standard therapies (24-1326)	1-3L metastatic RAS-mutated CRC, 1-2L metastatic RAS-mutated pancreatic cancer	NCT06445062	AMC, LT
Phase 1/2 study of M3814 + hypofractionated radiation for locally advanced pancreatic adenocarcinoma (20-2093)	Locally advanced pancreatic adenocarcinoma following 4-6 months of neoadjuvant chemo	NCT04172532	AMC
Phase 1 study of SGN-CEACAM5C advanced solid tumors including CRC, GC/GEJ, pancreatic cancer (23-2329)	2L+ advanced CRC, GC/GEJ or pancreatic cancer	NCT06131840	AMC
Phase 1 study of PF-07934040 (KRASi) in patients (24-1423)	Select advanced solid tumors with KRAS mutations	NCT06447662	AMC (POEMs)
Phase 1 study of CA-4948 (IRAK4/FLT3i) + gemcitabine+ nab-paclitaxel in metastatic pancreatic cancer (23-0613)	2-3L metastatic or unresectable pancreatic ductal adeno	NCT05685602	AMC
A Phase 1A/B Study to Evaluate the Safety and Tolerability Of EBC-129 As A Single Agent and In Combination with Pembrolizumab in Advanced Solid Tumours (23-0580)	Metastatic Pancreatic Adenocarcinoma	NCT05701527	AMC (POEMs)
Neuroendocrine Cancers			
COMPOSE: Study of peptide receptor radionuclide therapy with lutetium edotreotide v standard therapy for SSTR+ GI neuroendocrine tumors (21-3552)	Well-differentiated aggressive, grade 2/3, SSTR+ neuroendocrine tumors of gastroenteric or pancreatic origin	NCT04919226	AMC
NET Retreat: Phase 2 study of 177Lutetium retreatment v. everolimus in metastatic midgut neuroendocrine (23-1917)	Metastatic grade 1/2 midgut neuroendocrine tumors	NCT05773274	AMC

Genitourinary Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Cyndie Harvey	Cynthia.Harvey@uchealth.org	Phone: 720-848-0170 Fax: 720-848-0180
Physician	**Email**	**Phone**
Laura Graham, MD	Laura.graham@cuanschutz.edu	
Elizabeth Kessler, MD	Elizabeth.kessler@cuanschutz.edu	

Localized Prostate Cancer			
Study Name	**Patients**	**NCT#**	**Sites**
S2210: Neoadjuvant carboplatin for patients with localized prostate cancer and germline BRCA1/2 mutations (23-2420)	Localized prostate cancer with germline BRCA1/2 mutation	NCT05806515	AMC
Pragmatic study of metformin v. lifestyle mods (19-1536)	Localized prostate cancer	NCT05515978	AMC
Metastatic Prostate Cancer			
S1802: SST +/- surgery or radiation (18-2252)	Metastatic hormone sensitive prostate cancer	NCT03678025	AMC
NRG GU011: PROMETHEAN: Phase 2 trial of oligometastatic RT +/- androgen deprivation therapy (22-0504)	Oligometastatic hormone sensitive prostate cancer	NCT05053152	AMC, HRH (RT Group)
KEYNOTE-365: Study of pembrolizumab combinations COHORT I: Carbo/Etop +/- pembro (21-3724)	De novo and treatment emergent neuroendocrine/small cell prostate cancer	NCT02861573	AMC
MK-5684-003: Phase 3 study of opevesostat v. abiraterone/enzalutamide (24-0350)	Metastatic castration-resistant prostate cancer previously treated with hormonal agent and taxane	NCT06136624	AMC, HRH, LT
MK-5684-004: Phase 3 study of opevesostat v. abiraterone/enzalutamide (24-0742)	Metastatic castration-resistant prostate cancer previously treated with hormonal agent	NCT06136650	AMC, HRH, LT
JNJ-87189401 and JNJ-78278343 (23-1990)	Metastatic castration-resistant prostate cancer	NCT06095089	AMC
Phase 1b/2a study of pocenbrodib alone or in combination with abiraterone acetate, olaparib, or 177Lu-PSMA-617 (24-2278)	Metastatic castration-resistant Prostate Cancer	NCT06785636	AMC
CCTG-PR26 - Randomized phase 3 clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors (TRIPLE-SWITCH) (25-0680)	Metastatic castration-sensitive prostate cancer and suboptimal PSA response	NCT06592924	AMC CCMC LT HRH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer (25-1528)	Metastatic castration-resistant Prostate Cancer	NCT07164443	AMC
Bladder Cancer			

Phase 2 study of intravesicular instillation of TARA-002 (24-1264)	High grade non-muscle invasive bladder cancer	NCT05085990	AMC
EA8192 Preoperative durvalumab and/or chemo (21-3855)	Upper tract urothelial cancer	NCT04628767	AMC
MODERN: A032103 risk adapted adjuvant therapy - ctDNA testing and nivo+/- relatlimab or surveillance (24-0700)	Muscle invasive bladder cancer or upper tract urothelial cancer after surgery	NCT05987241	AMC
S1937: Eribulin + gemcitabine v. standard therapy (22-0927)	3L+ metastatic bladder cancer post PD1i	NCT04579224	AMC
Kidney Cancer			
SAMURAI: Phase 2 study of SABR in patients receiving immunotherapy (24-2480)	Metastatic unresectable RCC	NCT05327686	AMC, LT, HRH, CCMC
NEOPAX: Pembrolizumab + axitinib for RCC with IVC tumor thrombus (22-1669)	Neoadjuvant therapy for RCC with tumor thrombus	NCT05969496	AMC
HC-7366 + belzutifan for locally advanced or metastatic clear cell RCC (24-0745)	2L+ metastatic clear cell RCC	NCT06234605	AMC
STRIKE/A032201: Study of short term intensified pembrolizumab + tivozanib for high-risk renal cell carcinoma (25-0682)	Clear cell RCC following complete resection	NCT06661720	AMC HRH CCMC LT
Penile Cancer			
EA8134 InPACT: Neoadjuvant chemo + ILND v chemo +RT+ILND v ILND (17-1515)	Penile cancer	NCT02305654	AMC

Gynecologic Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Clinic schedulers	-	Phone: 303-724-2066
Marcela Mora (Spanish speaking)	Marcela.Mora@uchealth.org	Phone: 720-848-5474
Physician	**Email**	**Phone**
Brad Corr, MD	Bradley.corr@cuanschutz.edu	

Ovarian Cancer - Frontline			
Study	**Patients**	**NCT#**	**Sites**
GOG-3068 HOTT HIPEC: Phase 3 study of HIPEC + cisplatin v no HIPEC at time of cytoreductive surgery followed by niraparib in stage III and IV ovarian cancer (23-2189)	Newly diagnosed stage III/IV ovarian, primary peritoneal, and fallopian tube cancer treated with neoadj chemo	NCT05659381	AMC
Ovarian Cancer - Maintenance			
UPROAR: Phase 2 study of maintenance mirvetuximab soravtansine (ADC) and olaparib in recurrent platinum sensitive, ovarian cancer (22-0384)	Recurrent platinum-sensitive ovarian, peritoneal, and fallopian tube cancer	NCT05887609	AMC
NRG-GY036: Phase 3 trial of one vs. two years maintenance olaparib, +/- bevacizumab (25-0399)	BRCA1/2 mutated or HRD+ ovarian cancer following response to 1L platinum-based chemotherapy	NCT06580314	AMC CCMC HRH
Ovarian Cancer - Recurrent			
FONTANA: Phase 1/2a study of AZD5335 (ADC folate receptor + TOP1i) in solid tumors (23-2128)	Platinum-resistant or platinum-sensitive ovarian cancer	NCT05797168	AMC
VOLASTRA: Phase 1/2 study of VLS-1488 (KIF18Ai) in advanced high grade serous ovarian cancer (23-1991)	Recurrent platinum-resistant high grade serous ovarian cancer, ovarian carcinosarcoma, CN-high endometrial/uterine carcinosarcoma, uterine serous carcinoma	NCT05902988	AMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab (24-1128)	Previously treated metastatic HR+HER2- or TNBC, endometrial, or ovarian cancer	NCT06233942	AMC (POEMs)
A Phase 1b study of psilocybin assisted psychotherapy to address fear of recurrence in patients diagnosed with early-stage breast cancer and ovarian cancer in remission (23-1455)	Clinical stage 1 or 2, completed primary treatment, risk of recurrence at 10 years <20%	NCT06430541	AMC
Phase I study of CLK/DYRK (Cirtuvivint) + olaparib in BRCA/HRD platinum resistant ovarian cancer (24-1749)	Platinum-resistant ovarian cancer with 1-3 prior lines of therapy. BRCA or HRD + with prior parp inhibitor.	NCT06856499	AMC
Phase 1/2 study of MBRC-101 in select advanced solid tumors (23-2430)	Metastatic refractory Ovarian Adenocarcinoma	NCT06014658	AMC (POEMs)

Phase 2 Trial of the combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor talazoparib, in patients with molecularly-selected solid tumors (ComBET) (23-0145)	HRD tumors with prior PARPi use as immediate prior therapy	NCT05327010	AMC (POEMs)
Ovarian Cancer – Low Grade			
No current studies available			
Endometrial Cancer - Presurgical			
No current studies available			
Endometrial Cancer - Frontline			
NRG GY026: Phase 2/3 study of paclitaxel/carboplatin +/- hylecta or phesgo in HER2+ endometrial cancer (22-1764)	1L Stage I-IV endometrial serous carcinoma, carcinosarcoma, or other histology HER2+	NCT05256225	AMC, HRH, CCMC
NRG GY032: Phase 2 study of tailored adjuvant therapy in POLE-mutated p53 WT early stage endometrial cancer (24-1417)	1L Stage I-III endometrial cancer POLE-mutated, p53 WT, completed surgery	NCT06388018	AMC
Endometrial Cancer - Recurrent			
GOG-3082: Phase 1b/2 basket study of ACR-368 (CHK1/2i) +/-gemcitabine in platinum-resistant ovarian, endometrial and urothelial ca based on acrivon oncosignature (23-0115)	Up to 2L in recurrent setting: Recurrent, platinum-resistant ovarian cancer, endometrial adenoca, urothelial carcinoma with Acrivol Oncosignature Status	NCT05548296	AMC
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab (24-1128)	Previously treated metastatic HR+HER2- or TNBC, endometrial, or ovarian cancer	NCT06233942	AMC (POEMs)
Cervical Cancer			
NRG-GY037: A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer (25-2515)	High Risk Locally Advanced Cervical Cancer	NCT07061977	AMC, HRH
Uterine Leiomyosarcoma			
GOG 3088: Phase 2 study of letrozole v. observation in uterine leiomyosarcoma (24-0041)	Newly diagnosed ER+ uterine leiomyosarcoma	NCT05649956	AMC, HRH
BRCA Mutation Carriers			
SOROC: Study of salpingectomy v. salpingo-oophorectomy to reduce risk of ovarian cancer in BRCA1 carriers (20-2079)	BRCA1 germline mutation carriers with no prior cancer diagnosis age 35-50	NCT04251052	AMC, HRH

Head and Neck Cancer Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Kristen Miller	Kristen.Miller3@uchealth.org	Phone: 720-848-2639
Natalya Veneychuk	Natalya.Veneychuk@uchealth.org	Phone: 720-848-5456
Marcela Mora (Spanish speaking)	Marcela.Mora@uchealth.org	Phone: 720-848-5474
Physician	**Email**	**Phone**
Antonio Jimeno, MD, PhD	Antonio.jimeno@cuanschutz.edu	

Head and Neck Cancer			
Study Name	**Patients**	**NCT#**	**Sites**
Phase 1b/2 study of NT219 in combination with pembro or cetuximab (24-0689)	Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	NCT06919666	AMC, HRH
Phase 1 / 2 Study of REGN7075 (EGFRxCD28 bispecific ab) + cemiplimab (24-2232)	Select advanced solid tumors, including cutaneous squamous cell carcinoma, CRC, HNSCC	NCT04626635	AMC (POEMs)
FORTIFI-HN010: Phase 2/3 study of ficerafusp alfa (BCA101) v. placebo + pembrolizumab (25-0122)	1L PD-L1-positive, recurrent or metastatic NHSCC	NCT06788990	AMC
eVOLVE-HNSCC: Phase 3 study of volrustomig v. observation in unresected locally advanced HNSCC (23-2332)	Unresected locally advanced HNSCC who have not progressed following definitive concurrent chemoRT	NCT06129864	AMC, HRH
OrigAMI-4: Phase 1b/2 study of amivantamab monotherapy + standard therapy in recurrent/metastatic HNSCC (24-0472)	Locally Advanced treatment naive and eligible for surgery HNSCC	NCT06385080	AMC
Phase 1b study of losartan, pembrolizumab and SBRT in locoregionally recurrent refractory or oligometastatic HNSCC (24-1630)	locoregionally recurrent refractory or oligometastatic HNSCC	NCT06211335	AMC, HRH
NRG- HN010: Phase 2 study of docetaxel + trastuzumab v. T-DM1 for HER2+ salivary gland cancer (22-2363)	Recurrent, metastatic, or treatment-naïve, unresectable HER2+ salivary gland cancer	NCT05408845	AMC, HRH
EA3231: Phase 3 study of BRAF-targeted therapy v. cabozantinib in RAI-refractory differentiated thyroid cancers with BRAF V600E mutation (24-2273)	Advanced RAI-refractory differentiated thyroid cancers with BRAF V600 E mutation	NCT06475989	AMC, HRH

Hematology Clinical Trials Unit Anschutz Medical Campus (AMC)		
Nurse Navigator UCH-BDC Intake Team	**Email** UCH-BDCIntakeTeam20181018184924@uchealth.org	**Phone** 720-848-2595
Doc Line Phone: 720-848-2628 (doc line)		

Physician	Email	Phone
Leukemia: Dan Pollyea, MD	Daniel.pollyea@cuanschutz.edu	
Cell Therapy/Stem Cell Transplant: Jon Gutman, MD	Jonathan.gutman@cuanschutz.edu	
Lymphoma: Manali Kamdar, MD	Manali.kamdar@cuanschutz.edu	
Multiple Myeloma: Dan Sherbenou, MD, PhD	Daniel.sherbenou@cuanschutz.edu	
Benign Heme and MPNs: Brandon McMahon, MD	Brandon.mcmahon@cuanschutz.edu	

Leukemia			
Study	**Patients**	**NCT#**	**Sites**
A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-M11D1 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (PI: C. McMahon/ 25-0091)	Relapsed and/or refractory CD33 positive AML that has failed initial standard therapy	NCT06714591	AMC
Phase 1b study to evaluate eganelisib as monotherapy and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia (PI: McMahon, C/24-2332)	Relapsed/refractory AML; ECOG of ≤2; adequate organ function	NCT06533761	AMC
Phase I study of SNDX-5613 in patients with relapsed/refractory leukemias including those harboring an MLL/KMT2A gene rearrangement or nucleophosmin1 (NPM1) Mutation (PI: McMahon C/ 22-1050)	Relapsed/refractory AML; ECOG of ≤2; adequate organ function	NCT04065399	AMC
Phase I study of CD19 directed CAR T Cells in adult patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with minimal residual disease (MRD) positivity at first complete remission (PI: Schwartz/22-0054)	Ages ≥ 18; B-cell ALL in first complete morphologic remission; MRD positive; ECOG of ≤2	NCT05535855	AMC
Study of Mitoxantrone for venetoclax-resistant AML (PI: Kent/24-0178)	Non-APL AML by WHO criteria and have been treated with first-line venetoclax/HMA (azacitidine or decitabine)	NCT06429449	AMC
A controlled multi-arm phase 1 umbrella study evaluating the safety	Undergoing allogenic HCT for the following: AML (including	NCT05473910	AMC

and feasibility of T-cell receptor engineered donor T-cells targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 positive subjects undergoing allogeneic peripheral blood stem cell transplantation (PI: Angelos/24-1444)	mixed phenotype acute leukemia), MDS, and ALL.		
A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab vs. venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy (PI: McMahon/24-0685)	Diagnosis of AML according to ICC 2022 (with the exclusion of MDS/AML with 10-19% blasts). Previously untreated AML. Deemed unfit for intensive therapy.	NCT06384261	AMC
Study of cladribine + venetoclax after failure of venetoclax + hypomethylating agent in monocytic AML (PI: McMahon/23-0273)	Ages ≥ 18; Relapsed/Refractory AML; ECOG of ≤2	NCT06232655	AMC
KO-MEN-007: Phase 1 study of venetoclax/azacitidine or venetoclax + ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) + ziftomenib for AML (PI: McMahon/23-0061)	Ages ≥ 18; documented NPM1 mutation or KMT2A rearrangement and have either newly diagnosed or relapsed/refractory AML; ECOG of ≤2	NCT05735184	AMC
Phase I/2 Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-D22 Chimeric Antigen Receptor) in patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL) (PI: Angelos/ 22-1502)	Patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)	NCT04150497	AMC
Myelodysplastic Syndrome Trials			
A controlled multi-arm phase 1 umbrella study evaluating the safety and feasibility of T-cell receptor engineered donor T-cells targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 positive subjects undergoing allogeneic peripheral blood stem cell transplantation (PI: Angelos/24-1444)	Undergoing allogenic HCT for the following: AML (including mixed phenotype acute leukemia), MDS, and ALL.	NCT05473910	AMC
RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia (PI: McMahon, Brandon/25-1397)	DIPSS score of 3 to 4 (intermediate 2 risk) or ≥5 (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to WHO 2016 criteria	NCT05320198	AMC
Lymphoma			

Phase I study of patient-derived multi-tumor associated antigen specific T-cells (MT-601) in patients with relapsed/refractory non- hodgkin lymphoma (PI:Kamdar/23-0056)	Diagnosis of NHL, HL or CLL; ECOG or zero or 1; adequate organ function	NCT05798897	AMC
Phase 3 interim response adapted trial comparing standard therapy with immuno-oncology therapy for children and adults (PI: Milgrom/24-2065)	Newly diagnosed Stage I and II classic Hodgkins Lymphoma	NCT05675410	AMC (RT Group)
S2308: Randomized Phase 3 study of mosunetuzumab vs. rituximab for low tumor burden follicular lymphoma (PI: Kamdar/ 25-0024)	Participants must have a histologically confirmed diagnosis of Classic Follicular Lymphoma (cFL). Involvement of no more than 3 nodal or extra nodal sites with diameter greater than 3 cm.	NCT06337318	AMC
A Phase 1a/1b trial in relapsed/refractory T-cell non-hodgkin lymphoma to determine the safety profile, pharmacology, and maximum tolerated dose of ST-001, a fenretinide phospholipid suspension (12.5 mg/mL) for intravenous infusion (PI: Haverkos/24-0458)	Ages > 18; ECOG of 0-1; diagnosed CTCL or Nodal TCL	NCT04234048	AMC
Phase Ib Study of mosunetuzumab or glofitamab + CC-220 and CC-99282 in B-Cell Non-Hodgkin Lymphoma (PI: Kamdar/22-0939)	Ages ≥ 18; ECOG of ≤2	NCT05169515	AMC
Phase 1/1b study of bispecific CD19 and CD22 chimeric antigen receptorCo-expressing T cells (CD19x22 CAR T) in adolescent and adult patients with relapsed and/or refractory B-NHL (PI: Kamdar/21-2578)	Ages ≥ 16; Relapsed or refractory aggressive B-cell NHL; ECOG of 0 or 1	NCT05098613	AMC
Phase 3 Study comparing the combination of beleodaq-CHOP or folotyn-COP to the CHOP regimen alone (24-2331)	Newly Diagnosed Patients with Peripheral T-Cell Lymphoma	NCT06072131	AMC
Multiple Myeloma			
A Phase 1, study of CB-011, a CRISPR-edited allogeneic anti-BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma (CaMMouflage Trial) (PI: Sherbenou/23-0376)	Ages ≥ 18; Diagnosed MM and evidence of PD based on IMWG criteria; ECOG of ≤1	NCT05722418	AMC
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation MajesTEC-4 (PI: Monge/24-2397)	Newly diagnosed MM; post Auto stem cell transplant	NCT05243797	AMC

A phase 1b/2, open-label study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory multiple myeloma remission (PI: Monge Urrea/24-2523)	Ages ≥ 18; Received at least three prior MM treatment lines of therapy; Have received as part of their previous therapy a PI and IMiD and an antiCD38 antibody	NCT05850234	AMC
Benign Heme			
Phase 3 study of bomedemstat (MK-3543/IMG-7289) v. best available therapy (24-2052)	Essential thrombocythemia who have an inadequate response to or are intolerant of hydroxyurea	NCT06079879	AMC
RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia (PI: McMahon, Brandon/25-1397)	DIPSS score of 3 to 4 (intermediate 2 risk) or ≥5 (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to WHO 2016 criteria	NCT05320198	AMC
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms (PI: Mat Angelos/25-0787)	Positive for a calreticulin (CALR) driver mutation of essential thrombocythemia (ET) or myelofibrosis (MF	NCT06150157	AMC
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis (PI: Duarte/25-1016	Participant has confirmed diagnosis of ISM, confirmed by Central Pathology Review	NCT04910685	AMC
Allo Transplant/GVHD			
No active trials			

Neuro-Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Clinic scheduler	-	Phone: 720-848-0300
Ana Lara-Rocha	Ana.Lararocha@uchealth.org	Phone: 720-848-9264
Physician	**Email**	**Phone**
Denise Damek, MD	Denise.damek@cuanschutz.edu	

Neuro-Oncology			
Study	**Patients**	**NCT#**	**Sites**
Phase I Study of [177Lu] Lu-NeoB in combination with radiotherapy and	Newly diagnosed and recurrent GMB	NCT05739942	AMC

temozolomide in newly diagnosed glioblastoma and as a single agent in recurrent glioblastoma (24-0082)			
GBM AGILE: Phase 2/3 platform trial evaluating multiple regimens for glioblastoma (19-0744)	Newly diagnosed GBM	NCT03970447	AMC,
A071401 Phase 2 study of SMO/AKT/NF2 inhibitors in progressive meningiomas (15-1747)	Progressive meningiomas with AKT1, PIK3CA or PTEN mutations	NCT02523014	AMC
Protocol 10559 A Phase 2 study of erdafitinib in patients with recurrent or progressive IDH-wild type glioma with FGFR-TACC gene fusion (23-2578)	Recurrent and progressive gliomas	NCT05859334	AMC
A Phase 2, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in patients with isocitrate dehydrogenase 1 (IDH1)-mutant glioma (25-1162)	Recurrent or progressive WHO Grade 2 glioma or Grade 3 glioma with IDH1 R132H or R132C mutation	NCT05303519	AMC

Phase 1, Expansion, Molecular Studies (POEMs) Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Contact Disease Site Specific Nurse Navigator (ie Breast Cancer, GI, GU, etc.)		
Physician	**Email**	**Phone**
Jennifer Diamond, MD	jennifer.diamond@cuanschutz.edu	
Antonio Jimeno, MD, PhD	Antonio.jimeno@cuanschutz.edu	

POEMs Studies			
Study	**Patients**	**NCT#**	**Sites**
Phase I study of RO7673396 (pan-RASi) as single agent and in combination with other anticancer therapy (25-0860)	Advanced solid tumors with RAS mutations	NCT06884618	AMC
Phase 1 study of LY4050784 (selective SMARCA2/BRM inhibitor) (24-1841)	Advanced solid tumors with SMARCA4/BRG1 Alterations Priority NSCLC	NCT06561685	AMC (POEMs)
Phase 1 study of INBRX-109 (DR5 ab) in metastatic solid tumors (18-1672)	Ewings sarcoma	NCT03715933	AMC (POEMs)
Phase 1 study of R07502175 (CCR8i)+ pembrolizumab (22-1245)	NSCLC PD-L1 ≥ 50%, CPI naive	NCT05581004	AMC (POEMs)
Phase 1 study of PF-07799933 (RAFi) in advanced tumors with BRAF alterations (22-1125)	Metastatic CRC with BRAF V600E mutation	NCT05355701	AMC (POEMs)
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors (22-1490)	1L NSCLC PD-L1 TPS ≥ 50% 1L melanoma 2L melanoma	NCT05533697	AMC (POEMs)
ComBET: Phase 2 trial of ZEN-3694 (BETi) + talazoparib in advanced solid tumors (23-0145)	Advanced solid tumor prior PARPi +/-DDR (not BRCA1/2) mutation	NCT05327010	AMC (POEMs)
Phase 1 study of STX-478 (mutant selective PI3K inhibitor) (23-0200)	Metastatic HR+HER2- breast cancer with PIK3CA kinase and helical mutations	NCT05768139	AMC (POEMs)
Phase 1/2 study of MBRC-101 in select advanced solid tumors (23-2430)	Metastatic breast cancer, NSCLC (adeno and Sq Cell)	NCT06014658	AMC (POEMs)
Phase 1 study of BG-C9074 (B7H4 ADC) +/- tislelizumab (24-1128)	Metastatic breast, endometrial and platinum resistant ovarian	NCT06233942	AMC (POEMs)
Phase 1 study of PF-07934040 (KRASi) in patients (24-1423)	Select advanced solid tumors with KRAS mutations NSCLC G12D/V only	NCT06447662	AMC (POEMs)
Phase 1 / 2 Study of REGN7075 (EGFRxCD28 bispecific ab) + cemiplimab (24-2232)	Select advanced solid tumors, including cutaneous squamous cell carcinoma, HNSCC	NCT04626635	AMC (POEMs)
Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced Cancers Harboring HER2 tyrosine kinase domain mutations or HER2+	NCT06253871	AMC (POEMs)
Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with	KRASG12C mutated NSCLC	NCT06128551	AMC (POEMs)

Advanced KRASG12C-Mutated Solid Tumors (24-0554)			
An Open-label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects with Known Wnt-Pathway Activated Solid Tumors Where No Other Treatments Exist (25-2381)	Solid Tumors known to be Wnt-Pathway (CRC, Gastric, NSCLC, TNBC) activated with no other approved treatment options available	NCT07312903	AMC (POEMs)

Radiation Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Pam Miranda	Pamela.miranda@uchealth.org	Phone: 720-848-0224 Fax: 720-848-0113
Physician	**Email**	**Phone**
Christine Fisher, MD	Christine.fisher@cuanschutz.edu	
Rachel Rabinovitch, MD	Rachel.Rabinovitch@cuanschutz.edu-	

Radiation Oncology-Breast Cancer			
Study	**Patients**	**NCT#**	**Sites**
Tailor RT: Randomized study regional RT in low-risk node+ or T3N0 breast cancer (19-0476)	Low-risk node+ or T3N0M0 breast cancer following surgery	NCT03488693	AMC, CCMC, HRH, LT
DEBRA (BR007): Phase 3 trial of de-escalation of RT in stage I HR+HER2- breast cancer (21-4582)	Stage I, HR+, HER2- breast cancer with Oncotype RS ≤ 18	NCT04852887	AMC, CCMC, HRH
Radiation Oncology- Genitourinary Cancer			
NRG GU011: PROMETHEAN: Phase 2 trial of oligometastatic RT +/- androgen deprivation therapy (22-0504)	Oligometastatic hormone sensitive prostate cancer	NCT05053152	AMC, HRH
Radiation Oncology - Lymphoma			
Phase 3 interim response adapted trial comparing standard therapy with immuno-oncology therapy for children and adults (24-2065)	Newly diagnosed Stage I and II classic hodgkins lymphoma	NCT05675410	AMC
Radiation Oncology -Lung Cancer			
NRG-LU008: Phase 3 trial of primary lung SBRT followed by mediastinal chemo-RT locally advanced NSCLC (23-1258)	Locally advanced NSCLC	NCT05624996	AMC, LT, HRH
DURABLE: Delayed or upfront brain Radiotherapy (24-1615)	naïve lung cancer patients with asymptomatic or minimally symptomatic Brain metastases and ALK rearrangement	NCT05987644	AMC
Radiation Oncology-Pancreatic Cancer			
No currently active studies			
Radiation Oncology –Neuro Oncology			
Phase I Study of [177Lu] Lu-NeoB in combination with radiotherapy and temozolomide in newly diagnosed glioblastoma and as a single agent in recurrent glioblastoma (24-0082)	Newly diagnosed and recurrent GMB	NCT05739942	**A**MC
Radiation Oncology-Multiple Cancer Types			
NRG-BN013: PHASE 3 study of single fraction SRS for versus FSRS for intact brain metastases (24-2477)	Non-small cell lung cancer Melanoma Breast cancer Renal cell carcinoma Gastrointestinal cancer at least 1 and up to 8 total intact brain metastases and at least 1	NCT06500455	AMC

	of the up to 8 lesions must be a lesion with a maximum diameter of >/= 1.0 cm and </= 3.0 cm		
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients with Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates (25-1202)	Residual Adenocarcinoma after total neoadjuvant therapy	NCT07292298	AMC

Sarcoma Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Erica Becker, PA-C	Erica.becker@cuanschutz.edu	Phone: 720-848-9395 Fax: 720-848-5245
Sarah Reynolds, ONN-CG, RN	Sarah.Reynolds2@uchealth.org	Phone: 720-848-0201 Fax: 720-848-0160
Marcela Mora (Spanish speaking)	Marcela.Mora@uchealth.org	Phone: 720-848-5474
Physician	**Email**	**Phone**
Breelyn Wilky, MD	Breelyn.wilky@cuanschutz.edu	

Sarcoma			
Study	**Patients**	**NCT#**	**Sites**
Phase 1 study of peposertib (M3814) and low-dose liposomal doxorubicin (25-0217)	Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas	NCT05711615	AMC
STRASS 2 (EA7211): Phase 3 study of neoadjuvant chemo followed by surgery v surgery alone high-risk retroperitoneal sarcoma (23-1625)	High risk retroperitoneal sarcoma (LPS/LMS)	NCT04031677	AMC
EA7222: Phase 3 trial of doxorubicin +/- pembrolizumab undifferentiated pleomorphic sarcoma (24-2043)	Undifferentiated pleomorphic sarcoma and related poorly differentiated sarcomas	NCT06422806	AMC
Phase 1/2 study of ADI-PEG 20 or placebo plus gemcitabine and docetaxel in previously treated subjects with leiomyosarcoma (23-1728)	Leiomyosarcoma	NCT05712694	AMC
Phase 3 double blind randomized placebo-controlled study of ivosidenib in pts over 18 yo with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen (24-1378)	Locally advanced or metastatic conventional chondrosarcoma with IDH1 mutation	NCT06127407	AMC
A Phase I/Ib Study of losartan in combination with sunitinib in the treatment of pediatric and adult patients with relapsed or refractory osteosarcoma (18-2740)	Osteosarcoma	NCT03900793	CHCO, AMC
Phase 1 study of INBRX-109 (DR5 ab) in metastatic solid tumors (18-1672)	Ewings sarcoma	NCT03715933	AMC (POEMs)
A phase II study on efficacy and tolerability of weekly doxorubicin in elderly patients (24-0118)	Advanced or Metastatic Leiomyosarcoma of Soft Tissue	NCT07125183	AMC
Phase 1/2, open-label, dose escalation and expansion study of ADCE-D01, a humanized anti-human uPARAP antibody linked to a topoisomerase I inhibitor (24-2281)	Metastatic and/or Unresectable Soft Tissue Sarcoma	NCT06797999	AMC
Multi-cohort, open-label, Phase 1/2 study of DCC-3009 in participants with	GIST	NCT06630234	AMC

gastrointestinal stromal tumors (GIST) (24-2282)			
Phase 3 study of lurbinectedin + doxorubicin v. doxorubicin (SaLuDo) (25-0027)	1L metastatic leiomyosarcoma	NCT06088290	AMC
Phase 1 study of ziftomenib + imatinib (25-0466)	GIST after imatinib failure	NCT06655246	AMC

Thoracic (Lung) Oncology Anschutz Medical Campus (AMC)		
Nurse Navigator	**Email**	**Phone**
Courtney Sorensen, RN	Courtney.thoutt@uchealth.org	Phone: 720-848-2962 Fax: 720-848-0360
Physician	**Email**	**Phone**
Tejas Patil, MD	Tejas.patil@cuanschutz.edu	
Erin Schenk, MD, PhD	Erin.schenk@cuanschutz.edu	

Early-Stage NSCLC			
Study	**Patients**	**NCT#**	**Sites**
NAUTIKA-1: Phase 2 study of neoadjuvant and adjuvant biomarker-selected therapy for NSCLC (22-1484)	Stage IB-III NSCLC ALK fusion, (Neoadjuvant TKIs x 8 w), PD-L1+ > 1% (atezo + SBRT) (Only ALK Fusion Cohort open)	NCT04302025	AMC
V940-009: A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (24-2314)	Neo-adjuvant (Stage II-IIIB(N2)) NSCLC	NCT06623422	AMC
NRG-LU008: Phase 3 trial of primary lung SBRT followed by mediastinal chemo-RT locally advanced NSCLC (23-1258)	Locally advanced NSCLC	NCT05624996	AMC, LT, HRH (RT Group)
1st Line Metastatic NSCLC			
Phase 3 study of vonescimab v. pembrolizumab (25-0500)	First line Metastatic NSCLC with High PD-L1 expression	NCT06767514	AMC
Study of response of bony metastasis for patients on TKI or systemic treatment (19-0392)	NSCLC with completed molecular testing; receiving standard of care TKI or systemic therapy for actionable driver	NCT03958565	AMC, LT
M24-536: An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Pembrolizumab in Advanced or Metastatic Non- Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations (AndroMETa-Lung-536) (25-1049)	Advanced/Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations	NCT06772623	AMC
Phase 1 study of R07502175 (CCR8i) + pembrolizumab (22-1245)	NSCLC PD-L1 $\geq$ 50%, CPI naive		AMC (POEMs)
Phase 1 study of mRNA-4359 + pembrolizumab in advanced solid tumors (22-1490)	1L NSCLC PD-L1 TPS $\geq$ 50%	NCT05533697	AMC (POEMS)
EGFR mutant NSCLC			

LungMAP S1900G: Phase 2 study of osimertinib + capmatinib +/- ramucirumab (23-0936)	Metastatic NSCLC EGFR mutant with MET amplification as resistance	NCT05642572	AMC
Systimmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoisomerase payload) in metastatic NSCLC (23-2288)	Metastatic NSCLC with EGFR mutation	NCT05983432	AMC
Phase 1b/2 study of BG-60366 (EGFR CDAC protein degrader) for EGFRm NSCLC patients (25-0436)	Metastatic NSCLC with EGFR mutation	NCT06685718	AMC
ALK, ROS1, or RET rearranged NSCLC			
NVL-655 EAP: Expanded access program for NVL-665 (novel ALK TKI) (22-0814)	Metastatic NSCLC with ALK	NCT05384626	AMC
Expanded access treatment of zidesamtinib (NVL-520) (25-0792)	Advanced ROS1+ NSCLC or other ROS1+ solid tumors	NCT06797362	AMC
MET or HER2 altered NSCLC			
SWOG S1900K: Phase 2 study of tepotinib +/- ramucirumab for MET exon 14 skip NSCLC (24-0486)	MET exon skip metastatic NSCLC	NCT06031688	AMC
SystImmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoi payload) metastatic NSCLC (23-2288)	HER2 Exon 20 mutated metastatic NSCLC	NCT05983432	AMC
Phase 1/1b Study of IAM1363 (HER2/HER2 mutant TKI, CNS penetrant) (25-0333)	Advanced cancers harboring HER2 tyrosine kinase domain mutations or HER2+	NCT06253871	AMC (POEMs)
KRAS or BRAF altered NSCLC			
Phase 1 study of PF-07934040 (KRASi) in patients (24-1423)	Select advanced solid tumors with KRAS mutations, NSCLC G12D/V	NCT06447662	AMC (POEMs)
Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors (24-0554)	KRASG12C mutated NSCLC	NCT06128551	AMC (POEMs)
2nd Line and Beyond Metastatic NSCLC: ADCs, cytotoxics, radiation			
Phase 1/2 study of MBRC-101 in select advanced solid tumors (23-2430)	Metastatic NSCLC (adeno and SCC)	NCT06014658	AMC (POEMs)
2nd Line and Beyond Metastatic NSCLC: Immunotherapy agents and Small Molecules			
Phase 1 study of LY4050784 (selective SMARCA2/BRM inhibitor) (24-1841)	Advanced solid tumors with SMARCA4/BRG1 Alterations	NCT06561685	AMC (POEMs)
An Open-label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects with Known Wnt-Pathway Activated Solid Tumors Where No Other Treatments Exist (25-2381)	Solid Tumors known to be Wnt-Pathway activated (NSCLC) with no other approved treatment options available	NCT07312903	AMC (POEMs)
Small Cell Lung Cancer			
MAVERICK (S1827): MRI brain surveillance +/- cranial irradiation small-cell lung (20-0359)	Small-Cell Lung Cancer	NCT04155034	AMC, HRH
MK-6070-002: A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and	Relapsed/Refractory Extensive-Stage SCLC	NCT06780137	AMC

Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (25-0794)			
PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC) (25-2349)	Extensive Stage Small Cell Lung Cancer (ES-SCLC)	NCT06769126	AMC, North, South
SystImmune: Phase 1 study of BL-B01D1 (EGFR-HER3 bispecific ADC topoi payload) metastatic NSCLC (23-2288)	HER2 Exon 20 mutated metastatic NSCLC and SCLC	NCT05983432	AMC
Mesothelioma and Thymic Malignancies			
AZ Evolve: Phase 3 study of volrustomig (PD1/CTLA4 bispecific) + chemotherapy vs investigators choice (24-0442)	unresectable, untreated mesothelioma	NCT06097728	AMC

Satellite Site Contacts		
	Physician Leads	**Nurse Navigators**
CCMC	Scott Kono, MD 720-550-0270 (cell) (Scott.Kono@CUAnschutz.edu)	Lanie Wolff (lanie.wolff@uchealth.org) 720-516-9254
HRH	Elaine Lam, MD (Elaine.Lam@CUAnschutz.edu)	Tera Stewart (Tera.Stewart@CUAnschutz.edu) and Kara Ickler (Kara.Ickler@CUAnschutz.edu)
LT	Corbin Eule, MD (Corbin.Eule@CUAnschutz.edu)	Crystal Stribling (CrystalD.Stribling@uchealth.org)

Common Eligibility Criteria for Clinical Trials	
Performance Status	ECOG 0-1 Karnofsky Performance Status ≥ 60
Age	Age ≥ 18 years (ask for sarcoma trials)
Measurable disease	**Lesions that can be accurately measured in at least one dimension** with a minimum size requirement: • **For CT or MRI scans:** o The lesion must be **≥10 mm** in its longest diameter. o For lymph nodes, the short axis must be **≥15 mm** to be considered measurable. • **For physical exam or clinical measurement:** o The lesion must be **≥10 mm** in its longest dimension and should be measurable with a caliper or ruler. • **For ultrasound:** o Lesions can only be considered measurable if they are confirmed by CT or MRI measurements. **Non-Measurable Lesions:** • Lesions that do not meet the criteria above are classified as **non-measurable.** • Please note that bone lesions (unless there is soft tissue extension), pleural effusions, or ascites are **not** considered measurable disease.
Adequate organ and bone marrow function	**Bone marrow:** ANC ≥ 1.5, Hgb ≥ 9.0 (without recent transfusion), platelets ≥ 100 (without recent transfusion). **Hepatic:** AST and ALT < 2 x ULN, bilirubin < 2.0. **Renal:** CrCl ≥ 50 ml/min. **Cardiovascular:** No symptomatic congestive heart failure; no MI, CVA, or unstable angina in the past 6 months. **Pulmonary:** History of ILD requiring steroids (protocol dependent). **Neurologic:** If brain metastases are present, they must have been treated and not progressing.